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ABSTRACT
Ageing is a complex process of accumulation of molecular, cellular, and organ damage, leading to loss 
of function and increased vulnerability to disease and death, the rate and extent of which varies among 
individuals. Osteoarthritis (OA) is not only the most common joint disease, but is also one of the major 
causes of disability in people aged >65 years and is accompanied by comorbid conditions, increased 
mortality, and decreased quality of life. One of the major risk factors for OA is ageing. However, OA itself 
may be involved in the biological ageing process. This is likely to be in part a direct involvement, by 
contributing levels of systemic inflammation and sharing molecular pathways with biological ageing, such 
as mitochondrial damage leading to cell senescence. Although OA is not considered an inflammatory form 
of arthritis, there is evidence of subclinical low-grade inflammation in the whole joint and inflammatory 
processes play a key role in the disease pathogenesis. For instance, there is synovial inflammation 
(e.g., following injury), mechanically derived inflammation present due to biomechanical overloading of 
a joint, and systemic inflammation resulting from obesity. Systemic inflammation is often associated with 
frailty, and having a high concentration of inflammatory markers is predictive of incident frailty, some of 
which are known to increase with age and correlate with pain. In addition, OA may also contribute indirectly 
to biological ageing via the disability and pain resulting from it. Further research into the exact process 
linking OA and biological ageing, including frailty, is needed.
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INTRODUCTION
Osteoarthritis (OA) is the most common global 
chronic joint disease. The disease may affect single 
or multiple joints and even be generalised. OA is 
a chronic arthropathy affecting the entire joint, 
involving the cartilage, joint lining, ligaments, and 
underlying bone. In OA, cartilage loss, osteophyte 
formation (bone spurs), and subchondral bone 
sclerosis leads to pain, disability, and a reduction 
in quality of life.1 Structural changes, visible by 
radiography, include narrowing of the joint space, 
osteophyte formation, and bone remodelling 
around the joints. OA can arise in any synovial joint 
in the body but is most common in the large joints 
(knees and hips), hands, and spine.1 
OA is believed to result from both biomechanical 
and molecular changes in the joint brought about 
by injury, joint malalignment, obesity, ageing, 
and inflammation. OA is classified as idiopathic 
or secondary to anatomic abnormalities, trauma, 
or inflammatory arthritis. The American College 
of Rheumatology (ACR) criteria developed for 
hand, hip, and knee OA are intended to distinguish 
OA from other causes of symptoms and are 
best suited to clinical settings in which a high 
prevalence of other forms of arthritis and joint pain 
is expected. This is different from the definition 
used for epidemiological studies given the poor 
correlation between radiographic disease severity 
(joint damage) and the joint pain and functional 
impairment presented by a patient. Thus, OA can be 
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defined pathologically, radiographically, or clinically, 
but most epidemiological studies have relied upon 
radiographic features to characterise the disease.2
EPIDEMIOLOGY OF OSTEOARTHRITIS 
OA is one of the most disabling diseases in 
developed countries. Global estimates are that 9.6% 
of men and 18.0% of women >60 years of age 
have symptomatic (painful) OA. Eighty percent of 
patients with OA have limitations in movement and 
25% cannot perform their major daily activities.3 
World Health Organization (WHO) data also 
demonstrated that OA moved from the 12th to 
the 6th leading cause of years lost to disability or 
morbidity between 2002 and 2007. Increases in life 
expectancy and ageing populations are expected 
to make OA the fourth leading cause of disability 
by the year 2020.3
Individuals with OA (defined both symptomatically 
and radiographically) at the knee or the hip show 
a 55% excess in all-cause mortality. Diabetes 
(95% increased risk), cancer (128% increased 
risk), cardiovascular disease (38% increased risk), 
and the presence of walking disability at baseline 
(48% increased risk) are independently associated 
with the excess in all-cause mortality.4 Importantly, 
deaths from cardiovascular causes are higher 
in patients with walking disability due to OA 
(72% higher), even after adjustment for baseline 
covariates, indicating that there is an interplay 
between the underlying OA and the additional 
comorbid conditions, which result in a higher risk of 
mortality. Thus, although the main clinical symptoms 
of OA are pain and disability, the consequences 
of the disease are much more far reaching. 
Several risk factors that have been recognised to 
affect hip and knee OA are body weight, age, female 
sex, occupational activity and injury,2 congenital 
abnormalities and joint shape, meniscal tears, 
presence of OA at other joints (Heberden’s and 
Bouchard’s nodes), and foot and knee alignment, 
in addition to genetic predisposition. Furthermore, 
specific inter and intra-articular patterns of OA may 
represent subsets that have different risk factor 
profiles and disease courses. 
PAIN AND DISABILITY
IN OSTEOARTHRITIS
In general, the main symptom of OA is joint pain 
exacerbated by exercise and relieved by rest, 
although pain at rest or during the night is not 
uncommon in advanced disease. Knee pain due 
to OA is usually bilateral and is experienced in 
and around the knee. Hip pain due to OA is felt 
in the groin and anterior or lateral thigh. Hip OA 
pain can also be referred to the knee. Signs of 
OA include reduced range of joint movement, 
joint swelling/synovitis (warmth, effusion, synovial 
thickening), crepitus, periarticular tenderness, bony 
swelling, and deformity due to osteophytes.1
OA patients report with a diminished ability to 
perform the basic activities of daily living, such 
as climbing stairs or changing from a sitting to 
standing position.5 In the UK, a recent survey, 
‘OA Nation’, found that 81% of people with OA 
experience constant pain and face limitations 
in performing certain tasks.4
OSTEOARTHRITIS AND AGEING, 
MOLECULAR MECHANISMS OF 
CARTILAGE DEGENERATION
Although late-onset articular cartilage degeneration 
is common and age is one of the most important 
risk factors for the disease, the relationship 
between old age and OA is not fully understood.6 
In the past, it was believed that the link with age 
was due to ‘wear and tear’ of articular cartilage 
by continuous mechanical stress; we now know, 
however, that OA involves an active response to 
injury comprising remodelling of articular cartilage 
and subchondral bone, in addition to synovial 
inflammation and damage to other joint structures, 
such as ligaments and menisci.7
Biological ageing is a complex process and it 
is now widely accepted that ageing starts with 
molecular damage, leading to cell, tissue, and, 
ultimately, organ dysfunction.8 Extensive evidence 
from animal models and in vitro studies has shown 
that mitochondria contributes to specific aspects of 
the ageing process, including cellular senescence, 
chronic inflammation, and the age-dependent 
decline in stem cell activity.9
Perhaps the best known and most long-standing 
hypothesis to explain ageing is the free radical 
theory, which proposes a central role for the 
mitochondrion as the principle source of 
intracellular reactive oxygen species (ROS) leading to 
mitochondrial DNA (mtDNA) mutations (Figure 1).8,9
Over the past 10 years, substantial evidence 
has accumulated showing that differences in 
mtDNA haplogroups correspond to variations 
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in prevalence and progression of cartilage loss 
in large joint OA.10 The mtDNA haplotypes T, 
J, and the JT cluster, on the other hand, are 
significantly associated in populations from the 
USA, the Netherlands, and Spain, with radiographic 
incidence and progression of the disease.11 
Fernandez-Moreno et al.11 report that the mtDNA 
haplogroup J, the same haplogroup associated with 
lower OA prevalence, lower disease progression, 
and lower cartilage loss, is also associated with a 
significantly lower risk of incident knee OA. 
The functional relevance of these mitochondrial 
haplotypes has been recently shown, using 
cytoplasmic hybrid (cybrid) cell lines.10 Cybrids 
incorporate mitochondria from human subjects 
and perpetuate the mtDNA-encoded components 
while maintaining the nuclear background of 
different cybrid lines as constant;12 thus, allowing 
investigators to assess the influence of mtDNA 
variation on cell function. 
The cybrids carrying the haplogroup H produce 
higher adenosine triphosphate levels than those 
with the haplogroup J, but this higher energetic 
efficiency was accompanied by higher production 
of ROS and the proportion of cells that survived 
in the presence of hydrogen peroxide was almost 
half the number of cybrids with haplogroup J. 
In chondrocytes during OA, oxidative stress may 
act together with inflammatory and/or mechanical 
stress to accentuate catabolic processes 
by increasing the levels of ROS relative to 
antioxidants.13 The increased levels of ROS also 
contribute to the senescence secretory phenotype, 
in which the age-related decline in the responses of 
chondrocytes to anabolic growth factors is related 
to increased oxidative stress.14 The depletion of 
antioxidants promotes mitochondrial dysfunction in 
chondrocytes,15 which, in turn, can amplify the stress 
responses through increased production of nitric 
oxide and ROS and NF-κB signalling.15,16
Figure 1: Molecular ageing mechanisms and risk of osteoarthritis.
Various cellular signalling mechanisms, including a decrease in the action of sirtuins in mitochondria, 
are involved in the process of cellular ageing, resulting in an increase in reactive oxygen species and 
inflammation, and a decrease in autophagy (lysosome-mediated degradation of damaged proteins 
and organelles).56-58 These changes influence the expression of catabolic factors resulting in increased 
production of matrix metalloproteinases, aggrecanases, and pro-inflammatory cytokines, reduced TGF-β 
signalling, increase in TGF-β receptors ALK1/ALK5 ratio (a cause for elevated metalloproteinases-13 
expression in osteoarthritis), and reduced levels of collagen Type 2 and aggrecan synthesis.59 Mitochondrial 
dysfunction, inflammation, chondrocyte hypertrophy, and apoptosis all contribute to the development 
of osteoarthritis, with the resulting formation of osteophytes.
ALK: activin receptor-like kinase; ECM: extracellular matrix; ROS: reactive oxygen species; TGF: 
transforming growth factor. 
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These data, therefore, prove the functional relevance 
of mtDNA variation linked to risk of OA on cell 
function and survival and is in agreement with 
recent work by the same group showing that OA 
cartilage presents signs of early molecular ageing 
compared to healthy age-matched cartilage.6 
This increase in cartilage ageing may also reflect 
overall higher ageing in other organ systems and 
may be related to the higher rate of comorbidities 
seen in OA patients.17 Indeed, OA is also linked to 
biological ageing overall and strong links have 
been found between OA and frailty. An overview of 
some of the molecular mechanisms underlying the 
connection between cellular ageing and cartilage 
damage is presented in Figure 1.
OSTEOARTHRITIS AND 
SYSTEMIC INFLAMMATION
Although OA is not considered an inflammatory 
form of arthritis, there is evidence of subclinical 
low-grade inflammation in the whole joint and 
inflammatory processes play a key role in the 
disease pathogenesis.18 Synovitis (inflammation of 
the synovium) is a critical characteristic of OA and 
is often considered the driver of the OA process. 
However, inflammatory processes are initiated 
via mediators that are released not just by the 
synovium but by bone and cartilage too.18
The drivers of this inflammation are varied and 
several sources of inflammation are involved in OA 
pathogenesis. In the first instance, there is synovial 
inflammation, which also affects cartilage and bone. 
Following a traumatic injury or a repetitive micro 
trauma to a joint, fragmented cartilage within a 
joint space provokes a reaction from synovial cells. 
As the fragments are considered foreign bodies, 
the synovial cells release inflammatory mediators. 
These mediators activate chondrocytes and 
produce metalloproteinases (MMP), which promote 
cartilage destruction. These mediators also induce 
inflammatory cytokines and MMP by the synovium 
itself that perpetuates further destruction of the 
synovium. Altered rates of osteophyte remodelling in 
OA are due to increased or decreased osteoclastic 
bone resorption.19 There is evidence in the literature 
of chemical communication between chondrocytes 
and osteophytes.20 Inflammatory mediators such 
as cytokines can move between these tissues, 
consistent with the fact that OA is a disease of the 
whole joint. Moreover, mechanical inflammation 
is also present due to biomechanical overloading 
of a joint that is detected by mechanoreceptors 
located at the joint surface. An abnormal increase 
in joint loading increases the expression and 
release of inflammatory cytokines, chemokines, 
and prostaglandins.21 At an intracellular level, the 
mechanical forces are translated into chemical 
signals, also known as mechanotransduction, 
that trigger inflammation and gradual onset 
of OA. The presence of atherosclerosis-related 
inflammation and altered levels of adipokines offer 
a further contribution to systemic inflammatory 
processes in addition to joint-localised ones in OA. 
It is known that obesity induces an inflammatory 
environment, because adipose tissues express 
cytokines and adipocytokines that have been 
identified in the plasma and synovial fluid of OA 
patients.22-24 Obesity can also accelerate the OA 
process by inducing ischaemia at the subchondral 
level. The direct ischaemic effects on the bone 
are known to reduce cartilage nutrition and inflict 
multiple bone infarcts that are characteristic of 
advanced OA. Bone and cartilage remnants can be 
identified in the synovial and capsule space, with 
marked eburnation of bone surrounding the infarct. 
Adipokines also induce insulin resistance, endothelial 
dysfunction, and a systemic inflammation, which 
are implicated in atherosclerosis and could explain 
why OA patients have an almost 40% increased 
risk of cardiovascular disease.22 Adipokines play an 
important role in the pathogenesis of OA and 
have been shown to contribute to the formation 
of osteophytes.23,24 To date, the best-studied 
adipokines are adiponectin, leptin, visfatin, and 
resistin,25 and in animal models it has been shown 
that a local knee injection of visfatin inhibitor 
protects mice from developing mechanical OA.26
Inflammation in OA is also involved when an increase 
of inflammatory mediators means that a increased 
concentration of oxidised proteins accumulate 
within the joint. These ROS cause oxidative damage, 
which can trigger inflammation, promote cell 
senescence or ageing, and in particular, chondrocyte 
ageing (Figure 1). In ageing, there is a loss in the 
ability of cells and tissues to maintain homeostasis, 
particularly when placed under abnormal stresses 
such as oxidative stress or biomechanical 
overloading of a joint. This promotes stress-induced 
senescence of chondrocytes. Ageing also involves 
the formation of advanced glycation end-products 
(AGE), which are produced in ageing tissues. 
These end-products alter the mechanical properties 
of cartilage, which leads to more brittle tissue 
with an increased fatigue failure, and stimulate the 
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overproduction of pro-inflammatory cytokines and 
MMP.27 Overall, the integrity of the joint structure is 
compromised internally by inflammatory processes 
and externally by the systemic effects of ageing 
and mechanical loading.18 Therefore, while there 
appears to be a complex interplay between 
mediators and inflammatory processes affecting 
different joint structures, the overall effect over 
time is one of gradual degradation of tissues, 
loss of optimal joint integrity and function, and 
the onset of pain (Figure 2).
OSTEOARTHRITIS AND FRAILTY
Knee OA is not only a leading cause of functional 
limitation and disability in ageing adults, as 
described above,28 it is also strongly associated 
with another geriatric condition: frailty.29-31 Clinical 
frailty is considered highly prevalent in old age 
and predictive of a high risk of falls, worsening 
mobility, disability, hospitalisation, and death.32,33 
It is an increasing global public health burden with 
the reported prevalence of frailty in older people 
varying from between 5.6% in Germany29 to 42.6% 
in Chile.34
Knee OA and frailty are reported to share common 
risk factors such as obesity,35,36 with knee OA also 
associated with greater prevalence of developing 
frailty.30 Fried et al.32 proposed the definition of 
frailty as being when ≥3 of the following criteria 
were present: unintentional weight loss, self-
reported exhaustion, grip strength muscle weakness, 
slow walking speed, and low physical activity. 
Figure 2: Schematic representation of the link between osteoarthritis and biological ageing.
Age (years) 
40–55
55–70
70–85
BMI
Mitochondrial 
function
Cartilage damage
Pain and disability
Sarcopenia
Frailty
Mortality
Systemic inflammation
Healthy Osteoarthritis
EUROPEAN MEDICAL JOURNAL  •  March 2018  •  Creative Commons Attribution-Non Commercial 4.0 EMJ  EUROPEAN MEDICAL JOURNAL EUROPEAN MEDICAL JOURNAL  •  March 2018  •  Creative Commons Attribution-Non Commercial 4.0 EMJ  EUROPEAN MEDICAL JOURNAL 120 121
Patients with the presence of one or two frailty 
criteria are categorised as being in a pre-frail state. 
Castell et al.29 analysed older adults in six European 
countries and found the odds of pre-frailty and 
frailty were 1.54 and 2.96-times higher among OA 
than non-OA patients, respectively. 
Patients with knee OA have been reported to 
have slow walking speed,37 fatigue,38 low physical 
activity,39 whilst patients with hip OA have been 
reported to display all frailty criteria,40 suggesting 
that patients with OA often display frailty criteria. 
Unintentional weight loss is often not a characteristic 
of knee OA; on the contrary a large proportion 
of severe knee OA is attributable to obesity.41 
The underlying mechanisms associating knee OA 
and frailty are not yet understood, but their 
identification would provide novel targets for the 
management and prevention of frailty in adults.
INFLAMMATION AS A POTENTIAL 
MECHANISM LINKING OSTEOARTHRITIS, 
FRAILTY, AND SARCOPENIA
In older patients with OA there are positive 
relationships between pain, frailty, and sarcopenia 
(Figure 2), although the mechanisms behind the 
associations are not yet fully understood. In these 
aged patients, quadriceps muscle weakness has 
been reported to be present without knee pain, 
suggesting that the quadriceps weakness is a 
possible primary risk factor for knee pain and 
progression of joint damage in people with 
knee OA.42 
OA-related knee pain, along with quadriceps 
muscle weakness, can lead to a decrease in physical 
activity.43 This inactivity may lead to the loss of 
muscle mass; however, systemic inflammation has 
also been suggested as a potential mechanism 
that associates OA and frailty.30 Pain itself is a 
risk factor for the development of frailty. A recent 
prospective analysis, of 1,152 non-frail subjects 
at baseline, has demonstrated that lower limb 
OA-related pain was associated with an increased 
risk of developing frailty over 4.4 years, compared 
with people with OA and no pain.44
Age-related inflammation may not directly cause 
OA (as presented above) but is likely to act as 
contributing factors to its development and 
progression, as well as to increased pain and 
reduced physical function.45 Obesity associated 
with OA and ageing further contributes to the 
inflammatory environment, leading to muscle 
atrophy and sarcopenia through the production of 
high levels of inflammatory markers and cytokines, 
such as C-reactive protein (CRP), tumour necrosis 
factor (TNF)-α, interleukin (IL)-6, and IL-1-β.46 
TNF also contributes indirectly to sarcopenia by 
causing insulin resistance.
Both sarcopenia and obesity are independently 
associated with physical disability in elderly people. 
Sarcopenic obesity (age-related muscle atrophy 
in obese individuals) results in more physical 
limitations than sarcopenia or obesity alone, and 
has been strongly implicated in both risk of OA and 
frailty.47,48 Systemic inflammation is often associated 
with frailty; for example, having a high concentration 
of the inflammatory markers CRP and fibrinogen 
were predictive of incident frailty in women.49 
Higher levels of CRP have also been reported in 
women with early knee OA, as well as predicting 
those whose disease will progress over 4 years.50
There have been further systemic markers of 
inflammation, whose levels in the blood have been 
demonstrated to increase with age and correlate 
with pain. TNF-α, along with CRP, has been reported 
to be positively associated with knee pain over 
a 5-year study of older adults with OA,51 whilst 
higher serum levels of IL-6 are also considered to 
be associated with pain in early-stage knee OA.52 
Significant positive relationships have previously 
been identified between frailty and IL-6,53 with a link 
also being reported between elevated IL-6 and the 
loss of bone and muscle.54
The exact mechanism driving the relationship 
between inflammatory mediators, pain, OA, frailty, 
and sarcopenia is currently unknown. Inflammatory 
cytokines involved in frailty, including IL-1, IL-6, 
and TNF-α, are also increased in OA cartilage as 
opposed to normal cartilage.55 It is thought that 
a complex network of inflammatory cytokines 
including TNF-α, IL-1-β, and IL-10 are involved in 
the regulation of IL-6 and inflammation.54 Further 
research into the exact process is needed.
CONCLUSION
OA is the most common joint disease and is 
highly prevalent after 60 years of age. However, 
the presence of OA appears to also influence the 
risk of unhealthy ageing, both as the presence of 
cardiometabolic comorbidities and as a risk factor 
for the development of frailty and sarcopenia later 
in life (summarised in Figure 2). In this article, 
we have covered some of the evidence linking OA 
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